Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9245477 | 0.89 | THRB (0.46) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL9408746 | 0.83 | EGLN1 (0.47) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL9408853 | 0.79 | EGLN1 (0.44) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL22689371 | 0.79 | EGLN1 (0.44) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL2491678 | 0.78 | ALDH1A1 (0.44) | EGLN1GAAMGAMSIMGAM2 | |
| SCHEMBL2757934 | 0.76 | GAA (0.46) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL8272347 | 0.75 | TET2 (0.46) | EGLN1SMN1; SMN2ALDH1A1RAB9AKDM4E | |
| SCHEMBL9408856 | 0.75 | MAPT (0.47) | EGLN1MAPTHTTALDH1A1PKM | |
| SCHEMBL27996452 | 0.74 | GAA (0.44) | GAAMGAMSIMGAM2SMN1; SMN2 | |
| SCHEMBL29090601 | 0.74 | EGLN1 (0.40) | EGLN1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011012600-A1 | RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-03 | — | — | WO | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090105452-A1 | NON-FLUORESCENT QUENCHER COMPOUNDS AND BIOMOLECULAR ASSAYS | APPLERA CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | EGLN1 3469/4885GAA 1103/4885MGAM 4026/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | EGLN1 3987/4885GAA 2295/4885MGAM 4330/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | EGLN1 4209/4885GAA 2143/4885MGAM 4189/4885 |
| US-20090105452-A1 | NON-FLUORESCENT QUENCHER COMPOUNDS AND BIOMOLECULAR ASSAYS | DNTT, PNP, NT5C2 | EGLN1 2877/4885GAA 2986/4885MGAM 2854/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | EGLN1 3987/4885GAA 2295/4885MGAM 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.